7050 POSTER Multiple Docetaxel (DOC) Re-challenges (ReC) in Castration-resistant Prostate Cancer (CRPC) Patients (pts) – Outcomes and Predictive Factors of Response

2011 ◽  
Vol 47 ◽  
pp. S500
Author(s):  
O. Caffo ◽  
A. Caldara ◽  
A. Ferro ◽  
M. Frisinghelli ◽  
V. Murgia ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Predictive Factors ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer

2019 ◽  
Vol 75 (6) ◽  
pp. 920-926 ◽  
Author(s):  
Matthias M. Heck ◽  
Robert Tauber ◽  
Sebastian Schwaiger ◽  
Margitta Retz ◽  
Calogero D’Alessandria ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Treatment Outcome ◽  
Predictive Factors ◽  
Castration Resistant Prostate Cancer ◽  
Radioligand Therapy ◽  
Castration Resistant

Predictive factors of response to docetaxel (DOC) rechallenge (ReC) in castration-resistant prostate cancer (CRPC) patients (pts).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e15126-e15126
Author(s):  
A. Veccia ◽  
O. Caffo ◽  
S. Brugnara ◽  
A. Caldara ◽  
M. C. di Pasquale ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Predictive Factors ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Identification of a predictive factor of metastatic castration-resistant prostate cancer patients’ response to alternative antiandrogen therapy with flutamide.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 321-321
Author(s):  
Masato Yasui ◽  
Shuko Yoneyama ◽  
Koichi Uemura ◽  
Takashi Kawahara ◽  
Yusuke Hattori ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Hormone Therapy ◽  
Predictive Factors ◽  
Hormonal Therapy ◽  
Bone Scan ◽  
Second Line ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
N Stage

321 Background: Recently, new androgen pathway inhibitors, abiraterone and enzalutamide, are demonstrated to improve overall survival for metastatic castration-resistant prostate cancer (mCRPC). In Japan, alternative antiandrogen (AA) as second-line hormonal therapy for mCRPC that relapses after initial hormone therapy have been commonly used before new androgen pathway inhibitors. In this study, we attempted to identify the predictive factors for efficacy of AA as second-line hormone therapy. Methods: We identified consecutive 65 mCRPC patients treated with AA as second-line hormonal therapy. All patients were treated with maximum androgen blockade (MAB) initially and evaluated antiandrogen withdrawal syndrome after relapse. We analyzed the correlations between progression-free survival (PFS) of AA and clinicopathological characteristics, including patients’ age, initial PSA levels, PSA levels at flutamide induction, Gleason scores, T stage, N stage, extent of disease (EOD) classifications on bone scan, and the previous duration of prostate cancer sensitivity to MAB. Results: The median duration of prostate cancer sensitivity to MAB was 11.3 months (range: 1.5-53.0 months). In multivariate analysis, four significant risk factors for poor PFS were identified; initial PSA levels ( > 263 ng/mL vs ≤ 263; HR 0.53, p = 0.038), N stage (1 vs 0; HR 3.00, p = 0.001), EOD classifications (3-4 vs 1-2; HR 2.50, p = 0.007), and the previous duration of prostate cancer sensitivity to MAB ( < 12 months vs ≥ 12; HR 2.16, p = 0.026). We stratified the patients into two cohorts with low risk (0-2 risk factor present) and high risk (3-4 risk factors present). We found a significant difference in PFS among risk groups (median PFS 7.3 months vs 1.5, p < 0.000). Conclusions: Initial PSA, N stage, EOD classifications on bone scan, and the previous duration of prostate cancer sensitivity to MAB were the significant predictive factors for efficacy of AA as second-line hormone therapy in patients with mCRPC. These findings might support that decision-making of when to start the new AR pathway inhibitors.

Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer

2018 ◽  
Vol 38 (7) ◽  
pp. 4115-4121 ◽  
Author(s):  
TOMOHIKO MURAKAMI ◽  
HIROFUMI OBATA ◽  
NAOKO AKITAKE ◽  
MASAKI SHIOTA ◽  
ARIO TAKEUCHI ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Predictive Factors ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Androgen Withdrawal ◽  
Prognostic And Predictive Factors

scholarly journals A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer

2021 ◽  
Author(s):  
Yasuhide Miyoshi ◽  
Sohgo Tsutsumi ◽  
Masato Yasui ◽  
Takashi Kawahara ◽  
Ko-ichi Uemura ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prediction Model ◽  
Predictive Factors ◽  
Treatment Completion ◽  
Castration Resistant Prostate Cancer ◽  
Entire Cohort ◽  
Castration Resistant ◽  
Radium 223 ◽  
Group 3 ◽  
Group 2

Abstract Purpose We evaluated the predictive factors for completion of all six cycles of radium-223 (Ra-223) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). We also developed a novel prediction model for Ra-223 treatment completion using these predictors. Methods We retrospectively reviewed data from 122 patients with mCRPC who were treated with Ra-223. The predictive factors for the completion of six cycles of Ra-223 treatment were evaluated. Statistically significant predictive factors were then used to develop a prediction model for treatment completion. Finally, using this prediction model, we classified the overall survival (OS) of the entire cohort into three groups. Results We identified three significant variables as the predictive factors for treatment completion: baseline alkaline phosphatase (ALP) level, baseline hemoglobin (Hb) level, and baseline pain. The three groups generated using the prediction model were: group 1 (patients with three predictive factors, i.e., ALP < median, Hb ≥ median, and no pain), group 2 (patients with one to two predictive factors), and group 3 (patients without any predictive factors). The treatment completion rates differed between the three groups significantly. Furthermore, the OS also differed among the groups significantly. Conclusion Our study suggested that the baseline ALP level, baseline Hb level, and baseline pain were the predictive factors of completion of all six cycles of Ra-223 treatment in patients with mCRPC. Our prediction model consisting of these factors could predict not only the completion of Ra-223 treatment, but also the post-treatment survival. This model can thus be useful for selection of patients for Ra-223 treatment.

scholarly journals Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen

2020 ◽  
Author(s):  
Kai Huang ◽  
Imke Schatka ◽  
Julian M. M. Rogasch ◽  
Randall L. Lindquist ◽  
Maria De Santis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Predictive Factors ◽  
Specific Antigen ◽  
Standardized Uptake Value ◽  
Predictive Score ◽  
Prostate Specific Membrane Antigen ◽  
Castration Resistant Prostate Cancer ◽  
Radioligand Therapy ◽  
Castration Resistant ◽  
Specific Membrane

Abstract Objective Up to 60% of patients with metastatic, castration-resistant prostate cancer (mCRPC) treated with 177Lu prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) achieves a partial biochemical response with a decrease of > 50% in prostate-specific antigen (PSA) levels. The remaining fractions, however, do not respond to RLT. The aim of this explorative analysis was to identify pre-therapeutic factors for the prediction of response. Methods 46 patients [age = 68 years (50–87)] with mCRPC who consecutively underwent RLT with 177Lu PSMA [median applied activity = 6 GBq (2.9–6.2)] were included and analysed retrospectively. The association of different clinical and laboratory factors and parameters from pre-therapeutic 68Ga PSMA positron emission tomography (PET) with the outcome of RLT was tested (Fisher’s test). Outcome was defined as PSA changes 8 weeks after second RLT [partial response (PR), PSA decrease > 50%; progressive disease (PD), PSA increase ≥ 25%; stable disease (SD), others]. Significant predictive factors were combined in a predictive score. Results 30% showed a post-treatment PR (median 73% PSA decrease), 35% SD (median 17% PSA decrease) and 35% PD (median 42% PSA increase). Significant predictors for PD were alkaline phosphatase (ALP) > 135 U/l (p = 0.002), PSA > 200 ng/ml (p = 0.036), and maximum standardized uptake value (SUVmax) of the “hottest lesion” in pre-therapeutic PET < 45 (p = 0.005). The predictive score including PSA, ALP and SUVmax could separate 2 distinct groups of patients: ≤ 2 predictive factors (19% PD) and 3 predictive factors (90% PD). Conclusion The presented predictive score allowed a pre-therapeutic estimate of the expected response to 2 cycles of RLT. As our study was retrospective, prospective trials are needed for validation.

Sign in / Sign up

Export Citation Format

Share Document